PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

[HTML][HTML] The double-edged roles of ROS in cancer prevention and therapy

Y Wang, H Qi, Y Liu, C Duan, X Liu, T Xia, D Chen… - Theranostics, 2021 - ncbi.nlm.nih.gov
Reactive oxygen species (ROS) serve as cell signaling molecules generated in oxidative
metabolism and are associated with a number of human diseases. The reprogramming of …

Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

N Jiang, Q Dai, X Su, J Fu, X Feng, J Peng - Molecular biology reports, 2020 - Springer
Given that the PI3K/AKT pathway has manifested its compelling influence on multiple
cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in …

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

M Yuan, LL Huang, JH Chen, J Wu, Q Xu - Signal transduction and …, 2019 - nature.com
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …

CircRNA: a rising star in gastric cancer

R Li, J Jiang, H Shi, H Qian, X Zhang, W Xu - Cellular and Molecular Life …, 2020 - Springer
In recent years, a large number of circRNAs have been identified in mammalian cells with
high-throughput sequencing technologies and bioinformatics. The aberrant expression of …

Cancer‐associated fibroblast‐derived exosomal microRNA‐20a suppresses the PTEN/PI3K‐AKT pathway to promote the progression and chemoresistance of non …

L Shi, W Zhu, Y Huang, L Zhuo, S Wang… - Clinical and …, 2022 - Wiley Online Library
Abstract Background Cancer‐associated fibroblasts (CAFs) contributes to overall tumor
progression. In the current survey, we explored the ability of microRNA‐20a (miR‐20a) …

Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: a review

Y Guo, J Song, Y Wang, L Huang, L Sun, J Zhao… - Frontiers in …, 2020 - frontiersin.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …

The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications

P Icard, L Simula, L Fournel, K Leroy, A Lupo… - Drug Resistance …, 2022 - Elsevier
NSCLC is the leading cause of cancer mortality and represents a major challenge in cancer
therapy. Intrinsic and acquired anticancer drug resistance are promoted by hypoxia and HIF …

Nobiletin as an inducer of programmed cell death in cancer: a review

J Huang, Z Chang, Q Lu, X Chen, M Najafi - Apoptosis, 2022 - Springer
Cancer resistance to therapy is a big issue in cancer therapy. Tumours may develop some
mechanisms to reduce the induction of cell death, thus stimulating tumour growth. Cancer …

PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around

A Gkountakos, G Sartori, I Falcone, G Piro, L Ciuffreda… - Cancers, 2019 - mdpi.com
Lung cancer is the most common malignancy and cause of cancer deaths worldwide, owing
to the dismal prognosis for most affected patients. Phosphatase and tensin homolog deleted …